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Abstract
Bacground: Although the contribution of fibroblast growth factor (FGF)-2 and mesenchymal stromal cells
(MSCs) to bone formation is well known, few studies have investigated the combination of an autologous bone
graft with FGF-2 or MSCs for large bone defects.
Methods: We studied an atrophic non-union model with a large bone defect, created by resecting a 10-mm
section from the center of each femoral shaft of 12-week-old Sprague-Dawley rats. The periosteum of the
proximal and distal ends of the femur was cauterized circumferentially, and excised portions were used in the
contralateral femur as autologous bone grafts. The rats were randomized to three groups and given no further
treatment (group A), administered FGF-2 at 20 μg/20 μL (group B), or 1.0 × 106 MSCs (group C). Radiographs
were taken every 2 weeks up to 12 weeks, with CT performed at 12 weeks. Harvested femurs
were stained with toluidine blue and evaluated using radiographic and histology scores.
Results: Radiographic and histological evaluation showed that bone union had been achieved at 12 weeks in group
C, while group B showed callus formation and bridging callus but non-union, and in group A, callus formation alone
was evident. Both radiographic and histological scores were significantly higher at 2, 4, 6, 8, 10, and 12 weeks in groups
B and C than group A and also significantly higher in group C than group B at 12 weeks.
Conclusions: These data suggest that autologous bone grafts in combination with MSCs benefit difficult cases which
cannot be treated with autologous bone grafts alone.
Keywords: Large bone defects, Autologous bone grafts, Atrophic non-union model, Mesenchymal stromal cells (MSCs),
Fibroblast growth factor-2 (FGF-2)
Background
For bone defects or non-union, autologous bone grafts are
used daily in clinical practice. Although autologous bone
grafting is the gold standard, its ability to achieve bone
union under relatively poor conditions in the recipient site
such as large bone defects or atrophic non-union is not
promising. An autologous bone graft contains cells includ-
ing bone marrow mesenchymal stem cells (MSCs) and
several growth factors which induce bone formation in a
native bone structure. This raises the possibility that aug-
mentation of these factors could enhance the ability of a
graft to achieve bone union even under poor conditions.
Members of the fibroblast growth factor (FGF) family,
which comprises 23 subtypes, are present in most tissues
throughout the body and exert a variety of physiological
effects, while their abnormal expression causes human
genetic diseases such as achondroplasia or thanatophoric
dysplasia [1]. Among the FGF family members, FGF-2 is
known as a potent angiogenesis inducer and also has
bone-forming capacity. Several animal studies have dem-
onstrated its ability to enhance bone union. Kawaguchi
et al. reported that a single local application of FGF-2
promoted bone healing in the femur of normal and
diabetic rats [2]. In addition, FGF-2 stimulated healing
of segmental bone defects in rabbits [3] and accelerated
fracture healing by enhancing callus remodeling in
experimental dog tibial fractures [4]. Moreover, human
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clinical trials have been conducted to test whether bone
union can be accelerated by local injection of recombin-
ant human (rh)FGF at the fracture site [5].
Among the cells in the bone, MSCs have the ability to
differentiate into multiple lineages and are relatively easy
to obtain although it is necessary to culture the primary
cells to obtain sufficient numbers for clinical applica-
tions. MSCs have the capacity to differentiate into osteo-
blasts and therefore have become one of the most
promising cell sources in bone regenerative medicine. In
critical-sized segmental defects in the femurs of adult
athymic rats, there was significantly more new bone
formation at 12 weeks, and the bone formed was
stronger, in defects treated with mesenchymal stem cell-
loaded ceramic scaffolds than in scaffolds without MSCs
[6]. Furthermore, MSCs have the possibility to transmit
or release various conductive factors to induce new
vessel and bone formation [7–9].
We hypothesized that the combination of autologous
bone grafts with FGF-2 or MSCs could achieve bone
union even under quite poor conditions compared to
conventional bone grafts. The purpose of this study was
to verify whether bone union can be obtained using the
combination of autologous bone grafting with FGF-2 or
MSCs in an atrophic non-union model of a large bone
defect in the rat.
Methods
Animals
Male Sprague-Dawley rats aged 12 weeks (n = 18, weigh-
ing between 310 and 340 g; Shimizu Laboratory
Supplies, Kyoto, Japan) were used. They were housed
with free access to food and water and allowed unre-
stricted weight bearing. This study was approved by the
Ethics Committee for Experimental Animals of Hiroshima
University. All animals were treated according to the
guidelines stipulated by the Institutional Animal Care and
Use Committee.
Preparation of MSCs
A modification of Kotobuki’s culture method as
described previously [10, 11] was used for the isolation
and in vitro expansion of MSCs. The bone marrow was
flushed out of the femoral and tibial marrow cavities of
rats with a 21-gauge needle connected to a 10-mL
syringe containing 10 mL of culture medium composed
of high-glucose Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies, Grand Island, NY, USA),
10 % heat-inactivated fetal bovine serum (FBS; Sigma-Al-
drich Corp., St. Louis, MO, USA), and antibiotics (at a
final concentration of 100 units/mL penicillin, 100 μg/mL
streptomycin, and 0.25 μg/mL amphotericin B; Nacalai
Tesque, Kyoto, Japan). The cells were incubated in a hu-
midified atmosphere of 5 % CO2 and 95 % air at 37.0 °C.
The medium remained unchanged for the first 7 days and
was subsequently changed every 2–3 days. After 14–
21 days, the cells had proliferated and reached confluence.
The cells were then harvested using 0.25 % trypsin and
0.02 % EDTA, then rinsed twice with culture medium. To
expand the MSCs, 2–3 × 105 harvested cells were seeded
into 100-mm culture dishes. On reaching confluence again,
the cells were reseeded under the same conditions. We
confirmed that these cells had multi-differentiation ability
of osteogenesis, adipogenesis, and chondrogenesis [12].
Surgery
All surgical procedures were performed under normal
sterile conditions, and animals were anesthetized by
intraperitoneal administration of sodium 5-ethyl-5-bar-
biturate (50 mg/kg). Non-union was induced in the
bilateral femurs by creating a large bone defect and
cauterizing the periosteum. Prior to surgery, the extrem-
ities were shaved and prepared in a sterile fashion. In
each rat, both femurs were operated on and the femoral
shafts on both sides were used for harvesting of the
autologous bone for grafts. The bone grafts were
harvested through a lateral incision. The muscle and
periosteum were stripped circumferentially and the
distal and proximal ends of the mid-shaft of the femur
were osteotomized transversely using an oscillating
power saw, then a 10-mm length of the mid-shaft of
the femur was removed surgically. After removing the
mid-shaft of the femur, the periostea were cauterized
circumferentially at a distance of 2 mm on both ends of the
femur to create non-union. An autologous graft of bone re-
moved from the right femur was transplanted to the left
femur, and the left side was transplanted to the right side.
The bone grafts and femoral ends were then fixed in
apposition with a single intramedullary 2.0-mm diameter
K-wire, and the wound was closed in layers (Fig. 1).
The rats were randomized to three groups: group A
(N = 6) received the autologous bone graft alone, group
B (N = 6) was treated with an autologous bone graft
together with FGF-2 (Peprotech, Rocky Hill, NJ, USA),
and group C (N = 6) was treated with an autologous
bone graft together with MSCs. The dose of FGF-2 was
20 μg per 20 μL, and MSCs were used at a density of
1.0 × 106 cells/20 μL according to the previous reports
[12, 13].
Evaluation
Radiographic images were taken 2, 4, 6, 8, 10, and
12 weeks after surgery. According to the method
described in a previous report [14], radiographic images
were scored as follows: 0, no apparent hard callus; 1,
slight intramembranous ossification; 2, hard callus with-
out bridging of the fracture gap, fracture line is apparent;
3, hard callus with bridging of the fracture gap, fracture
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gap is noticeable; 4, unclear boundary between the newly-
formed hard callus and existing cortical bone; and 5, re-
modeling. Radiographic images were scored on each set of
four cortices, and all four cortex scores were summed.
The rats were sacrificed 12 weeks after surgery by
intraperitoneal injection of a lethal dose of sodium
pentobarbital, both femurs were harvested, and the
K-wires were removed. The harvested bones were
imaged by computed tomography (CT) using a SkyScan
1176 (SkyScan, Aarteselar, Belgium) with an isotropic
voxel size of 18 μm, energy settings of 50 kV and
500 μA, and no filter. Then, the femurs were prepared
for histology including toluidine blue staining. The
femurs were fixed in 4 % paraformaldehyde for 24 h and
then decalcified in KCX (FALMA, Tokyo, Japan) for ap-
proximately 12 h. After that, the femurs were
dehydrated in alcohol and embedded in paraffin. The
central section of each femur was cut into 5-μm-thick
sections using a microtome, and the sections were
stained with toluidine blue. According to the classification
of Allen et al. [15], the degree of fracture healing was
scored as follows: 0, pseudoarthrosis (most severe form of
arrest in fracture repair); 1, incomplete cartilaginous union
(retention of fibrous elements in the cartilaginous plate);
2, complete cartilaginous union (well-formed plate of hya-
line cartilage uniting the fragments); 3, incomplete bony
union (presence of a small amount of cartilage in the
callus); and 4, complete bony union. Histological evalu-
ation of fracture healing was scored on both the proximal
and distal ends of the fracture.
Statistical analysis
All results in this study are expressed as the mean ±
standard deviation (SD). Comparison among three
groups was performed using the Tukey–Kramer post
hoc test. P values of less than 0.05 were considered to be
statistically significant.
Results
In the radiographs at 2 weeks, no callus formation was
evident in any group. However, there was obvious callus
formation on the proximal and distal sides of the femur
and on both sides of the autologous bone graft in groups
B and C at 4 weeks while callus formation was only
present on the proximal and distal sides of the femur
with no callus on the autologous bone graft in group A.
Bridging callus formation could be observed at 6 weeks
in group C and was also observed at 10 weeks in group
B. In group A, there was no bridging callus formation at
12 weeks. The bridging callus in group C was remod-
eled, and bone union was observed at 12 weeks (Fig. 2).
The radiographic scores in groups B and C were
Fig. 1 Atrophic non-union model of a large bone defect. In each rat, the bilateral femoral shafts were used for harvesting of the autologous bone
graft. The mid-shaft of the femur was surgically removed and used as an autologous bone graft, 10 mm in length. The autologous bone removed
from the right femur was transplanted to the left femur, and the left side was transplanted to the right side
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significantly higher than that in group A and there was
no significant difference between groups B and C at 2, 4,
6, 8, or 10 weeks. At 12 weeks, the radiographic score in
group C was significantly higher than that in group B
(Table 1) (Fig. 3). In CT images, there was abundant
callus formation around the junction of femur and bone
graft in all groups; however, there was no bridging callus
formation in group A or B. In contrast, complete bone
union could be observed in group C (Fig. 4).
The histological findings showed that in groups B and
C, endochondral ossification with abundant chondro-
cytes and newly-formed woven bone were present
around the junction of the femur and the bone graft.
Bridging callus formation was observed in both groups B
and C. However, the gap between the bone graft and the
femur was not filled with callus in group B while bone
union was observed in group C. In group A, the gap was
filled with fibrous tissue (Fig. 5). The histological score
in group C was significantly higher than all other groups,
while the score in group B was significantly higher than
that in group A (Table 1) (Fig. 6).
Discussion
For the treatment of a bone defect or non-union, autolo-
gous bone grafting is recognized as the gold standard
method, and in fact good results have been obtained in
the clinical setting. However, autologous bone grafts
may not necessarily give promising results in cases with
large bone defects, poor conditions at the recipient site,
or use of inappropriate fixation procedures between the
fracture site and bone graft [16, 17]. In addition, harvest-
ing of autologous bone for grafting has several disadvan-
tages including limited harvest volume and pain or
fracture at the donor site [18]. To overcome these
problems, alternative procedures including the use of
artificial bone or some modification of the bone grafting
procedure such as the Masquelet technique have been
developed [19]. However, a complicated procedure like
the Masquelet technique requires multiple surgeries and
the results are not promising. As for artificial bone, bone
union is rarely obtained in large bone defects and conse-
quently many trials to improve bone union using a
combination of artificial bone and cells or growth factors
Fig. 2 Plain radiogram in each group. Autologous bone grafting in a rat model was performed by transplanting the mid-section of the femoral
shaft from the right femur to the left, and vice versa, with no further treatment (group A) or in conjunction with FGF-2 at 20 μg/20 μL (group B)
or MSCs (1 × 106 cells in 20 μL). In group A, there was good callus formation but no callus around the autologous bone graft. In group B, there
was good callus formation but no bridging. In contrast in group C, there was good callus formation and bridging at 6 weeks, while by 12 weeks,
the callus volume was reduced to less than that in groups A or B, but bone union was achieved at 12 weeks
Table 1 Radiographic and histological score
Radiographic score Histological score
2 weeks 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks
Group A (n = 6) 0.20 (±0.45) 3.40 (±1.52) 5.60 (±2.30) 7.8 (±0.45) 8.60 (±1.95) 8.80 (±1.79) 8.60 (±2.07)
Group B (n = 6) 4.00 (±2.00) (a) 10.00 (±1.73) (a) 10.67 (±1.53) (a) 13.00 (±1.00) (a) 13.00 (±1.00) (a) 13.00 (±1.00) (a) 12.33 (±0.58) (b)
Group C (n = 6) 3.60 (±0.55) (a) 8.20 (±3.03) (a) 11.0 (±1.41) (a) 13.40 (±2.19) (a) 15.00 (±2.44) (a) 18.33 (±1.53) (a)(b) 18.40 (±1.14) (a)(b)
Radiographic score and histological score / mean (± SD) (P value)
Statistically significant differences were identified based on the Tukey–Kramer post hoc test (a, P < 0.05 compared to group A; b, P < 0.05 compared to group B)
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have been conducted [20]. Ito et al. demonstrated that a
composite of MSCs with an interconnected porous
structure could enhance osteogenic potential, and that
some injected MSCs were able to survive and differenti-
ate into osteoblasts in the presence of an immunosup-
pressive agent, resulting in good bone formation [21]. A
study by Nakasa et al. also demonstrated that a prefabri-
cated vascularized bone graft created using FGF-2
administration and vascular bundle implantation into an
interconnected porous structure composite had the
ability to achieve bone union when transplanted into a
bone defect, although further experimental studies are
needed to enhance bone formation sufficiently for
clinical use [22]. In addition, artificial bone itself has
been improved. Indeed, these approaches to treatment at
bone defect or non-union sites where it is difficult to obtain
good results are important, but other ways to improve au-
tologous bone grafting should also be explored. In this
study, we evaluated the efficacy of the combination of an
autologous bone graft in conjunction with MSCs or FGF-2
in achieving bone union under quite poor conditions.
Proliferation of immature mesenchymal cells is stim-
ulated by FGF-2, but differentiation of osteoblastic cells
is inhibited [23–25]. A study using injected 125I-labeled
rhFGF-2 in hydrogel found that levels of rhFGF-2 were
reduced to half at the fracture site within 1 to 2 days,
with approximately 20, 3, and 1 %, respectively, of the
125I-labeled rhFGF-2 remaining at 1, 2, and 3 weeks at
the local site [2, 26]. Therefore, the effect of FGF occurs
at a relatively early stage of bone union during prolifera-
tion of immature mesenchymal cells. FGF promotes the
induction and differentiation of bone morphogenetic
proteins (BMPs), transforming growth factor β (TGF- β),
and prostaglandins [2, 25, 27] so that FGF may have the
ability to initiate the cellular and molecular cascade of
the osteogenic process during fracture healing.
Fig. 3 Radiographic scores in each group. The radiographic scores in groups B and C were significantly higher than that in group A and there
was no significant difference between groups B and C at 2, 4, 6, 8, and 10 weeks. At 12 weeks, the radiographic score in group C was significantly
higher than that in group B
Fig. 4 CT images in each group at 12 weeks. In CT images, there was abundant callus formation around the junction of femur and bone graft in
all groups; however, there was no bridging callus formation in group A or B. In contrast, complete bone union could be observed in group C
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Recently, because of advances in tissue engineering
techniques, cell-based treatments such as MSCs have
begun to be used in the treatment of various diseases
[28, 29]. MSCs have the capacity to differentiate into
osteoblasts, and furthermore, MSCs also have the
possibility to transmit or release various conductive factors
which contribute to vessel and bone formation [30–32]. In
bone union, MSCs play an important role in the bone
regenerative mechanism. Granero-Molto et al. and Undale
et al. demonstrated that transplanted MSCs enhanced
callus volume, increased new bone volume, and improved
biomechanical properties and could induce fracture heal-
ing by increasing biomechanical properties in mice and in
a non-union nude rat model [33, 34].
In the current study, the use of an autologous bone graft
in combination with MSCs resulted in good bone union
while the combination with FGF-2 was not ultimately able
to obtain bone union at 12 weeks although good callus
formation was exhibited. The half-life of FGF-2 is reported
to be in the range of 46 ± 21 min [35], and the physio-
logical activity of FGF-2 is limited to the early phase after
bone grafting. Therefore, in a situation which requires a
long time to obtain bone union, the effect of FGF-2 might
not last throughout the bone formation process.
In contrast, MSCs not only have the potential to them-
selves differentiate into osteoblasts but they also have
the ability to induce differentiation of other progenitor
cells and to recruit cells. Moreover, MSCs secrete
humoral factors including cytokines and microvesicles.
Throughout the process of bone formation, MSCs
contribute to the differentiation into osteoblasts of both
transplanted and endogenous MSCs and to the recruit-
ment of these cells for bone formation by secretion of
humoral factors, and these effects together subsequently
result in complete bone union.
There are several criticisms of this study. Firstly, our
non-union model in rat femur is quite different from the
atrophic non-union model which has been previously
reported [36]. We aimed to perform bone grafting into a
poor condition site and evaluate the effect of MSCs or
FGF-2 in combination with an autologous bone graft,
using a non-union model in which the mid-shaft of the
femur was surgically removed and the periostea were
cauterized circumferentially at a distance of 2 mm on
both ends of the femur. Typically, in clinical practice, an
autologous bone graft is taken from the iliac crest. In the
rat, the iliac bone is very thin, so that it is difficult to
obtain an autologous bone graft from this site. There-
fore, instead of the iliac bone, we used the harvested
mid-shaft of the femur as an autologous bone graft,
transplanting from the right femur to the left and from
the left femur to the right. Under poor conditions for
bone grafting, the combination of MSCs with an autolo-
gous bone graft resulted in good union. Secondly, in
many previous studies, because the half-life of FGF-2 is
very short, FGF-2 has been administered loaded into a
gelatin sheet. In actual clinical applications, it is difficult
to use gelatin sheets at the present moment and the
administration technique is complicated. Consequently,
in our study, a single-dose injection of FGF-2 or MSCs
into the bone graft was performed in order to mimic the
method of application that could be used in the clinic.
In the clinical setting, the use of multiple applications of
Fig. 5 Histological analysis in each group at 12 weeks. In histological images, there was abundant callus formation in groups A and B, but any
bridging at the fracture gap by the callus was not observed, and the fracture gap was still visible. In contrast, bone union was apparent in group C.
Original magnification ×40
Fig. 6 Histological score in each group at 12 weeks. The histological
score was highest for group C in three groups. Group B was
significantly higher than group A
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FGF-2 and MSCs is not feasible, and our results showed
that a single-dose application of MSCs produced good
bone union.
Conclusions
In conclusion, the combination of MSCs with an autolo-
gous bone graft was able to produce good bone union
for the treatment of a large bone defect or non-union.
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